$3.23
-0.04(-1.22%)
Mkt Cap $16M
$2.82
$15.97
52-Week Range
At a Glance
AI-generated8-K
Hyperion DeFi, Inc. furnished its Q4 and FY 2025 financial results via press release (Exhibit 99.1), reporting Q4 GAAP revenue of $496,229, Non-GAAP Adjusted Gross Profit of $820,997 (up 87% QoQ), and FY 2026 Adjusted Gross Profit guidance of $4M-$6M. The Board approved Third Amended and Restated Bylaws on March 20, 2026, reducing stockholder meeting quorum to one-third and permitting stockholder actions by written consent.$16M
Market Cap
$2M
Revenue
-$171M
Net Income
Employees13
Fundamentals
How The Business Makes Money
A U.S.-based firm pivoting from ophthalmic drug-delivery tech (Optejet) to becoming the first Nasdaq-listed U.S. company with a cryptocurrency treasury denominated in HYPE tokens from the Hyperliquid blockchain; also operates a validator (“Kinetiq × Hyperion”) and continues DeFi staking strategies alongside ongoing development of Optejet UFD™ for eye care.
Industry Medical - Devices
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001682639
ISINUS30234E2037
CUSIP30234E104
Phone917 289 1117
Address295 Madison Avenue, New York, NY, 10017, US
SEC EDGAR